Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.

Cancer research - 16 Sept 2022

Sorokin Alexey V, Kanikarla Marie Preeti, Bitner Lea, Syed Muddassir, Woods Melanie, Manyam Ganiraju, Kwong Lawrence N, Johnson Benny, Morris Van K, Jones Philip, Menter David G, Lee Michael S, Kopetz Scott

Abstract excerpt

KRAS and NRAS mutations occur in 45% of colorectal cancers, with combined MAPK pathway and CDK4/6 inhibition identified as a potential therapeutic strategy. In the current study, this combinatorial treatment approach was evaluated in a co-clinical trial in patient-derived xenografts (PDX), and safety was established in a clinical trial of binimetinib and palbociclib in patients with metastatic colorectal cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Tyrosine

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 35913398
DOI: 10.1158/0008-5472.CAN-22-0198
PMCID: PMC9478530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.PMID 35913398Read ↗

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Semantic proximity Read ↗

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.Semantic proximity Read ↗

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinomaSemantic proximity Read ↗

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.Semantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.Semantic proximity Read ↗

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.